Neovacs S.A. (EPA:ALNEV)
France · Delayed Price · Currency is EUR 0.0750
-0.0114 (-13.19%)
Nov 10, 2026, 3:57 PM CET
Neovacs Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 0.12 | 0.16 | 0.29 | 0.53 | 0 | 0.02 |
Other Revenue | 0.69 | 0.24 | 0.14 | - | - | - |
| 0.81 | 0.4 | 0.43 | 0.53 | 0 | 0.02 | |
Revenue Growth | 188.74% | -7.59% | -18.65% | 47868.71% | -95.07% | -24.32% |
Cost of Revenue | 2.66 | 2.67 | 3.2 | 4 | 3.4 | 4.56 |
Gross Profit | -1.85 | -2.27 | -2.77 | -3.47 | -3.4 | -4.54 |
Selling, General & Admin | 1.76 | 1.83 | 3.03 | 3.12 | 2.71 | 2.96 |
Other Operating Expenses | 1.03 | 1.06 | 0.63 | 0.15 | 0.18 | 0.23 |
Operating Expenses | 2.95 | 3.08 | 3.85 | 3.44 | 3.04 | 3.29 |
Operating Income | -4.81 | -5.35 | -6.62 | -6.91 | -6.44 | -7.83 |
Interest Expense | -0.94 | -0.94 | - | - | - | -0 |
Interest & Investment Income | - | - | 1.16 | 4.19 | 4.22 | 0.19 |
Currency Exchange Gain (Loss) | - | - | - | -0.14 | -0.07 | 0 |
Other Non Operating Income (Expenses) | 1.23 | 0.76 | -28.02 | -6.08 | -0.9 | -2.06 |
EBT Excluding Unusual Items | -4.52 | -5.53 | -33.49 | -8.94 | -3.19 | -9.7 |
Gain (Loss) on Sale of Investments | - | - | -1.25 | -0.33 | -0.08 | -0.18 |
Asset Writedown | - | - | -0.01 | - | - | -0 |
Other Unusual Items | - | - | 0.79 | -0.35 | -1.08 | -2.6 |
Pretax Income | -4.52 | -5.53 | -33.95 | -9.62 | -4.35 | -12.48 |
Income Tax Expense | -0.43 | -0.63 | -1.03 | -0.88 | -0.8 | -0.64 |
Net Income | -4.09 | -4.9 | -32.91 | -8.74 | -3.55 | -11.84 |
Net Income to Common | -4.09 | -4.9 | -32.91 | -8.74 | -3.55 | -11.84 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | - | - | - | - | 241 | 2 |
Shares Outstanding (Diluted) | - | - | - | - | 241 | 2 |
Shares Change | - | - | - | - | 12025.88% | -99.70% |
EPS (Basic) | - | - | - | - | -0.01 | -5.95 |
EPS (Diluted) | - | - | - | - | -0.01 | -5.95 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -4.17 | -5.04 | -3.68 | -2.12 | -4.6 | -10.26 |
Free Cash Flow Per Share | - | - | - | - | -0.02 | -5.15 |
Operating Margin | -593.40% | -1334.11% | -1525.96% | -1294.97% | -579583.27% | -34725.65% |
Profit Margin | -504.93% | -1221.13% | -7585.07% | -1639.15% | -319109.98% | -52512.21% |
Free Cash Flow Margin | -514.44% | -1256.72% | -848.26% | -396.80% | -413782.37% | -45498.69% |
EBITDA | -3.39 | -4.33 | -6.43 | -6.74 | -6.29 | -7.73 |
D&A For EBITDA | 1.41 | 1.02 | 0.19 | 0.16 | 0.15 | 0.1 |
EBIT | -4.81 | -5.35 | -6.62 | -6.91 | -6.44 | -7.83 |
Revenue as Reported | 0.81 | 0.4 | 0.51 | 0.54 | 0.01 | - |